- Home
- AXIL vs ANTX Comparison
AXIL vs ANTX Comparison
Compare AXIL & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- ANTX
- Stock Information
- Founded
- AXIL 2015
- ANTX 2017
- Country
- AXIL United States
- ANTX United States
- Employees
- AXIL N/A
- ANTX N/A
- Industry
- AXIL Package Goods/Cosmetics
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- ANTX Health Care
- Exchange
- AXIL Nasdaq
- ANTX Nasdaq
- Market Cap
- AXIL 43.9M
- ANTX 41.8M
- IPO Year
- AXIL N/A
- ANTX 2022
- Fundamental
- Price
- AXIL $5.02
- ANTX $1.40
- Analyst Decision
- AXIL
- ANTX Hold
- Analyst Count
- AXIL 0
- ANTX 5
- Target Price
- AXIL N/A
- ANTX $3.50
- AVG Volume (30 Days)
- AXIL 12.2K
- ANTX 96.0K
- Earning Date
- AXIL 04-09-2025
- ANTX 03-25-2025
- Dividend Yield
- AXIL N/A
- ANTX N/A
- EPS Growth
- AXIL 135.54
- ANTX N/A
- EPS
- AXIL 0.25
- ANTX N/A
- Revenue
- AXIL $26,554,439.00
- ANTX N/A
- Revenue This Year
- AXIL N/A
- ANTX N/A
- Revenue Next Year
- AXIL N/A
- ANTX N/A
- P/E Ratio
- AXIL $19.77
- ANTX N/A
- Revenue Growth
- AXIL N/A
- ANTX N/A
- 52 Week Low
- AXIL $3.54
- ANTX $0.87
- 52 Week High
- AXIL $13.24
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- AXIL 26.94
- ANTX 54.19
- Support Level
- AXIL $6.83
- ANTX $1.28
- Resistance Level
- AXIL $7.53
- ANTX $1.55
- Average True Range (ATR)
- AXIL 0.67
- ANTX 0.07
- MACD
- AXIL -0.24
- ANTX -0.01
- Stochastic Oscillator
- AXIL 8.81
- ANTX 40.74
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.